Clinical Trial

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 17, 2023 (before its estimated August 2024 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study was to evaluate the efficacy of anlotinib hydrochloride capsules combined with penpulimab injection (test group) versus placebo (control group) for adjuvant therapy after radical surgery or ablation in HCC patients with high risk of recurrence by assessing recurrence-free survival (RFS).
Trial Details
NCT Number NCT05862337
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Hepatocellular Carcinoma
Enrollment 480 participants
Start Date 2023-05-10
Primary Completion 2024-08 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2023-05-17